CATX
Perspective Therapeutics, Inc. AMEX Listed Nov 10, 2005$3.60
Mkt Cap $265.6M
52w Low $1.96
39.2% of range
52w High $6.16
50d MA $4.56
200d MA $3.63
P/E (TTM)
-2.8x
EV/EBITDA
19.0x
P/B
1.4x
Debt/Equity
0.0x
ROE
-49.8%
P/FCF
-2.1x
RSI (14)
—
ATR (14)
—
Beta
1.87
50d MA
$4.56
200d MA
$3.63
Avg Volume
3.5M
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
350 Hills Street · Seattle, WA 99354 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | AMC | -0.37 | -0.51 | -37.8% | 5.22 | -0.8% | -5.2% | -6.9% | -11.9% | -14.8% | -18.8% | — |
| Nov 10, 2025 | AMC | -0.33 | -0.35 | -6.1% | 2.22 | -3.2% | +0.0% | -4.5% | -6.8% | -6.3% | -0.5% | — |
| Aug 13, 2025 | AMC | -0.30 | -0.30 | +0.0% | 3.81 | -0.3% | +2.4% | -5.2% | -3.1% | -10.2% | -11.3% | — |
| May 12, 2025 | AMC | -0.28 | -0.25 | +10.7% | 2.51 | +4.0% | +1.6% | -13.9% | -4.0% | +4.8% | +8.8% | — |
| Mar 26, 2025 | AMC | -0.26 | -0.25 | +3.8% | 2.27 | -1.3% | +1.3% | -3.1% | -6.2% | -13.7% | -9.7% | — |
| Nov 12, 2024 | AMC | -0.21 | -0.21 | +0.0% | 10.67 | +0.9% | -6.9% | -16.4% | -26.1% | -34.8% | -36.5% | — |
| Aug 12, 2024 | AMC | -0.21 | -0.17 | +19.0% | 12.09 | -9.0% | +5.7% | +10.3% | +15.5% | +11.6% | +17.1% | — |
| May 15, 2024 | AMC | -0.30 | -0.20 | +33.3% | 15.70 | +0.0% | -2.5% | +1.9% | +3.8% | +1.3% | -5.1% | — |
| Feb 15, 2024 | AMC | -0.04 | -0.02 | +50.0% | 8.71 | -1.3% | +0.8% | +5.1% | +6.7% | +9.1% | +10.2% | — |
| Nov 14, 2023 | AMC | -0.40 | -0.40 | +0.0% | 2.32 | +10.8% | +8.6% | +11.6% | +12.1% | +6.5% | +11.2% | — |
| Aug 11, 2023 | AMC | -0.30 | -0.40 | -33.3% | 4.78 | -5.2% | -1.7% | -5.2% | -16.3% | -19.2% | -14.0% | — |
| May 15, 2023 | AMC | -0.01 | -0.01 | +0.0% | 6.50 | -12.3% | -21.5% | -30.2% | -27.1% | -25.2% | -21.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | Wedbush | Maintains | Outperform → Outperform | — | $4.20 | $4.58 | +9.0% | +8.3% | +10.5% | +12.1% | +7.4% | +7.4% |
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.45 | $4.55 | +2.2% | -4.7% | -3.6% | +1.6% | -5.2% | -8.5% |
| Mar 18 | B. Riley Securities | Maintains | Buy → Buy | — | $4.95 | $5.01 | +1.2% | -1.8% | -7.1% | -10.1% | -14.3% | -13.3% |
| Mar 18 | Wedbush | Maintains | Outperform → Outperform | — | $4.95 | $5.01 | +1.2% | -1.8% | -7.1% | -10.1% | -14.3% | -13.3% |
| Mar 18 | UBS | Maintains | Buy → Buy | — | $4.95 | $5.01 | +1.2% | -1.8% | -7.1% | -10.1% | -14.3% | -13.3% |
| Mar 17 | RBC Capital | Maintains | Outperform → Outperform | — | $5.22 | $5.18 | -0.8% | -5.2% | -6.9% | -11.9% | -14.8% | -18.8% |
| Mar 17 | BTIG | Maintains | Buy → Buy | — | $5.22 | $5.18 | -0.8% | -5.2% | -6.9% | -11.9% | -14.8% | -18.8% |
| Jan 30 | Wedbush | Maintains | Outperform → Outperform | — | $4.26 | $4.74 | +11.3% | -11.0% | +18.8% | +22.1% | +19.7% | +8.7% |
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.26 | $4.74 | +11.3% | -11.0% | +18.8% | +22.1% | +19.7% | +8.7% |
| Jan 13 | BTIG | Maintains | Buy → Buy | — | $2.41 | $2.44 | +1.2% | +4.1% | +8.7% | +2.9% | -3.3% | +0.8% |
| Nov 21 | UBS | Maintains | Buy → Buy | — | $2.12 | $2.12 | +0.0% | -1.4% | +2.4% | +3.3% | +5.2% | +10.8% |
| Nov 18 | B. Riley Securities | Maintains | Buy → Buy | — | $2.21 | $2.18 | -1.4% | +3.2% | +4.1% | -4.1% | -5.4% | -1.8% |
| Oct 13 | BTIG | Maintains | Buy → Buy | — | $4.86 | $5.20 | +7.0% | -0.6% | -0.4% | +2.5% | -2.3% | -7.6% |
| Oct 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.49 | $3.53 | +1.1% | +4.3% | +1.7% | -0.6% | +10.6% | +10.6% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.29 | $3.31 | +0.6% | -3.0% | +0.3% | -3.6% | -0.9% | -3.0% |
| Jun 23 | Wedbush | Maintains | Outperform → Outperform | — | $3.46 | $3.47 | +0.3% | +18.8% | +10.4% | +10.1% | +4.6% | +8.7% |
| Jun 23 | B. Riley Securities | Maintains | Buy → Buy | — | $3.46 | $3.47 | +0.3% | +18.8% | +10.4% | +10.1% | +4.6% | +8.7% |
| Jun 3 | RBC Capital | Maintains | Outperform → Outperform | — | $2.39 | $2.44 | +2.1% | +29.3% | +31.0% | +30.5% | +38.9% | +35.1% |
| May 14 | Truist | Maintains | Buy → Buy | — | $2.55 | $2.54 | -0.4% | -15.3% | -5.5% | +3.1% | +7.1% | +11.0% |
| Apr 7 | Truist | Maintains | Buy → Buy | — | $1.80 | $1.78 | -1.1% | +0.0% | -5.0% | +5.6% | +3.3% | +8.3% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.20 | $2.16 | -1.8% | -3.2% | -10.9% | -6.8% | -10.9% | -18.2% |
| Mar 27 | Wedbush | Maintains | Outperform → Outperform | — | $2.27 | $2.24 | -1.3% | +1.3% | -3.1% | -6.2% | -13.7% | -9.7% |
| Mar 27 | RBC Capital | Maintains | Outperform → Outperform | — | $2.27 | $2.24 | -1.3% | +1.3% | -3.1% | -6.2% | -13.7% | -9.7% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.45 | $2.45 | +0.0% | -3.7% | +1.6% | +2.9% | +2.9% | +0.8% |
| Jan 14 | RBC Capital | Maintains | Outperform → Outperform | — | $3.40 | $3.40 | +0.0% | -5.9% | -3.8% | -7.1% | +0.9% | +3.5% |
| Nov 25 | BofA Securities | Downgrade | Buy → Neutral | — | $3.47 | $3.55 | +2.3% | +6.3% | +26.8% | +18.7% | +25.4% | +19.6% |
| Nov 25 | RBC Capital | Maintains | Outperform → Outperform | — | $3.47 | $3.55 | +2.3% | +6.3% | +26.8% | +18.7% | +25.4% | +19.6% |
| Nov 22 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.00 | $3.06 | +2.0% | +15.7% | +23.0% | +46.7% | +37.3% | +45.0% |
| Oct 24 | Wedbush | Maintains | Outperform → Outperform | — | $11.69 | $12.28 | +5.0% | +1.7% | -1.4% | +1.9% | +1.5% | -1.9% |
| Oct 11 | Oppenheimer | Maintains | Outperform → Outperform | — | $13.25 | $11.50 | -13.2% | -4.5% | -7.2% | -5.2% | -1.9% | -8.3% |
| Aug 16 | RBC Capital | Maintains | Outperform → Outperform | — | $13.96 | $13.92 | -0.3% | -3.4% | +1.4% | +6.1% | +9.7% | +7.6% |
| Aug 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.09 | $11.00 | -9.0% | +5.7% | +10.3% | +15.5% | +11.6% | +17.1% |
| Jun 18 | Oppenheimer | Maintains | Outperform → Outperform | — | $10.34 | $10.68 | +3.3% | +15.4% | +3.0% | -2.4% | -0.4% | -7.6% |
| Jun 14 | RBC Capital | Maintains | Outperform → Outperform | — | $11.60 | $12.90 | +11.2% | -7.8% | -10.9% | +2.8% | -8.2% | -13.0% |
| May 16 | Jones Trading | Maintains | Buy → Buy | — | $15.70 | $15.70 | +0.0% | -2.5% | +1.9% | +3.8% | +1.3% | -5.1% |
| Apr 9 | B. Riley Securities | Maintains | Buy → Buy | — | $14.90 | $15.00 | +0.7% | +4.0% | +2.0% | -4.7% | -1.3% | +2.7% |
| Apr 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $11.90 | $12.50 | +5.0% | +7.6% | +22.7% | +21.0% | +19.3% | +24.4% |
| Mar 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $9.65 | $11.50 | +19.2% | +16.1% | +24.4% | +38.9% | +31.6% | +30.6% |
| May 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.74 | $4.75 | +0.2% | +2.5% | +7.6% | +8.6% | +6.3% | +5.3% |
| Feb 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.20 | $17.90 | +4.1% | +2.3% | +1.2% | -5.2% | -3.5% | +2.9% |
| Nov 8 | Maxim Group | Downgrade | Buy → Hold | — | $4.81 | $4.90 | +1.9% | -7.9% | -18.9% | -19.8% | -14.8% | -18.3% |
No insider trades available.
8-K · 8.01
!! High
Perspective Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
I cannot provide a meaningful analysis as the summary lacks substantive information about the material event or announcement beyond exhibit filing confirmation.
Apr 20
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
CATX disclosed a material event without specifying details, creating uncertainty about whether this represents positive news like a partnership or negative developments like litigation, leaving investors unable to assess immediate stock impact.
Apr 1
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Positive clinical data readout in 2026 from ASCO-GI symposium suggests Perspective's pipeline progress, potentially validating cancer treatment candidates and supporting future revenue prospects if regulatory approval follows.
Mar 16
8-K · 8.01
!! High
Perspective Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Perspective Therapeutics announced a public offering on February 2, 2026, and updated its investor presentation the following day.
Feb 3
8-K · 8.01
!! High
Perspective Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Perspective Therapeutics posted a presentation to its website on February 2, 2026, though the filing provides no details about the presentation's content or potential impact.
Feb 2
Data updated apr 24, 2026 11:58pm
· Source: massive.com